BioSpace News Archive

AppliedVR, a leading pioneer of therapeutic virtual reality (VR), and S.O.L.V.E. Health Tech, a health equity accelerator embedded within the University of California San Francisco, today announced a collaborative research project to identify barriers and facilitators to digital therapeutics, including VR treatment from AppliedVR, for vulnerable populations such as Medicaid patients

Cannabics Pharmaceuticals Inc. announced that in a series of tests conducted at the company’s High Through-put Screening facility in Israel, it has been shown that the cannabinoids CBC and CBG both exhibit anti-tumor properties, tested on human Gastrointestinal Cancer Cells.

Trial met primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2 positive metastatic gastric cancer

The completion of enrollment in the anti-GBM study marks an important milestone for the Company’s expansion outside transplantation. Anti-GBM is a rare immunological disease with a significant unmet medical need

Exact Sciences Corp. announced that the company plans to release its fourth-quarter and full-year 2019 financial results after the close of the U.S. financial markets on Feb. 11, 2020.

Industry-first sperm biology platform drives understanding of how differences in sperm can impact the most important aspects of the reproductive journey

Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today sent a letter to shareholders in connection with its efforts to elect two highly-qualified, fresh voices – Fabian Blank and Peter Clemens – to the Company’s Board of Directors (the “Board”) at its 2019 Annual Meeting of Shareholders

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), and Ocumension Therapeutics, today announced an exclusive license agreement for the development and commercialization of DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in Mainland China,

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), announced that, after reviewing the latest acquisition proposal in consultation with its advisors, Sorrento’s Board of Directors (the “Board”) determined that the offer significantly undervalues Sorrento and is not in the best interest of the Company’s stockholders.

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2019.